Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(OMER, GTIV, UEPS, CLNO) Noticeable Stock by

Stock-PR Reporting



FREE Daily Stock Alerts From




Omeros Corporation (NASDAQ:OMER) announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery. OMS302, one of Omeros' proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during cataract and other lens replacement surgery to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain and inflammation.

Read full article and disclaimer at :